首页> 美国卫生研究院文献>other >Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

【2h】

Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

机译：复发/难治性B细胞非霍奇金淋巴瘤患者抗CD22抗体-药物缀合吡妥珠单抗Vedotin联合利妥昔单抗治疗的I期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposePinatuzumab vedotin is an antibody–drug conjugate with the potent antimicrotubule agent monomethyl auristatin E (MMAE) conjugated to an anti-CD22 antibody via a protease-cleavable linker. This phase I study determined its recommended phase II dose (RP2D) and evaluated its safety, tolerability, and antitumor activity alone and with rituximab in relapsed/refractory (r/r) non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

机译：目的Pinatuzumab vedotin是一种抗体-药物偶联物，其有效的抗微管剂单甲基澳瑞他汀E（MMAE）通过蛋白酶可裂解的接头与抗CD22抗体偶联。这项I期研究确定了其推荐的II期推荐剂量（RP2D），并评估了其单独，与利妥昔单抗联合用于复发/难治性（r / r）非霍奇金淋巴瘤（NHL）和慢性淋巴细胞性白血病（CLL）的安全性，耐受性和抗肿瘤活性。

著录项

期刊名称 other
作者
Ranjana H. Advani; Daniel Lebovic; Andy Chen; Mark Brunvand; Andre Goy; Julie E. Chang; Ephraim Hochberg; Sreeni Yalamanchili; Robert Kahn; Dan Lu; Priya Agarwal; Randall C. Dere; Hsin-Ju Hsieh; Surai Jones; Yu-Waye Chu; Bruce D. Cheson;
展开▼
作者单位

展开▼
年(卷),期 -1(23),5
年度 -1
页码 1167–1176
总页数 21
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [J] . Advani Ranjana H., Lebovic Daniel, Chen Andy, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第5期

机译：在复发/难治性B细胞非霍奇金淋巴瘤患者中，I阶段研究抗CD22抗体 - 药物共轭疙瘩蛋白vEdotin，用/不含Rituximab患者
2. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study [J] . Palanca-Wessels Maria Corinna A., Czuczman Myron, Salles Gilles, The lancet oncology . 2015,第6期

机译：抗CD79B抗体-药物偶联物Polatuzumab vedotin在复发或难治性B细胞非霍奇金淋巴瘤和慢性淋巴细胞性白血病中的安全性和活性：一项1期研究
3. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma [J] . OguraM., HatakeK., AndoK., Cancer science. . 2012,第5期

机译：抗CD22免疫缀合物inotuzumab ozogamicin联合利妥昔单抗治疗复发/难治性B细胞非霍奇金淋巴瘤的I期研究
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Safety tolerability and preliminary activity of IMGN529 a CD37-targeted antibody-drug conjugate in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation phase I study [O] . Anastasios Stathis, Ian W. Flinn, Sumit Madan, -1

机译：IMGN529（一种靶向CD37的抗体-药物偶联物）在复发性或难治性B细胞非霍奇金淋巴瘤患者中的安全性耐受性和初步活性：剂量递增I期研究
7. Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma [O] . Ranjana H. Advani, Daniel Lebovic, Andy Chen, 2016

机译：在复发/难治性B细胞非霍奇金淋巴瘤患者中，I阶段研究抗CD22抗体 - 药物共轭疙瘩蛋白vEdotin，用/不含Rituximab患者

Phase I Study of the Anti-CD22 Antibody–Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅